Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 14.25
High: 14.25
Low: 14.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re US Venture -- Aberro

17 Nov 2005 07:02

Angle PLC17 November 2005 For Immediate Release 17 November 2005 ANGLE PLC US VENTURE, ABERRO: PRODUCT IN BETA TRIALS ANGLE is delighted to announce that it has officially launched Aberro, asoftware testing company (formerly known as ContraSoft). Aberro is 57 per cent.owned by ANGLE and is ANGLE's first US venture founded since ANGLE's flotationin 2004. Aberro has developed a beta release of its product, AberroTest, which is in useat several companies. The product solves a number of issues in the softwareindustry and is expected to be released commercially later this year. Aberro ispreviewing the technology at STARWEST, the world's largest software testingevent, which is being held this week in Anaheim, California. A recent IDC report projected that in 2006, companies will spend over $1 billionon tools to help improve their software testing capabilities. Aberro's AdaptiveAutomated Testing delivers easy and rapid test creation, with no programmingskills required, coupled with low-cost execution that automatically adapts tochanges in the target application. With Aberro's technology, tests areautomatically created in a matter of minutes. This allows testers to find andrepair defects sooner and more easily, while reducing development costs andimproving overall software quality. In developing Aberro, ANGLE has assembled an experienced management team headedby CEO Douglas Smith and Vice President of Marketing Steve Lafferty. Smithjoined the company from ANGLE, where he served as an Entrepreneur in Residence.He has over 20 years of management experience, including CEO and COO roles atthree start-up companies and senior management positions at Digital Equipment,Compaq and EMC. Lafferty previously served as Business Unit Director withManugistics and has held senior-level marketing roles at Cadre, Iona, SterlingSoftware and Green Hills Software. Additionally, Aberro's Co-Founder and CTO William Rogers, Ph.D., brings over 20years of research and development experience to the team. Rogers was theoriginator of Aberro's revolutionary software testing technique, AdaptiveAutomated Testing, which enables rigorous automated testing of software farearlier than any other solution on the market. Rob Kornblum, Managing Director of ANGLE Ventures (US) said: "We are delighted with our progress at Aberro in delivering product to betausers so rapidly. We already see a tremendous amount of interest in Aberro'sproducts from the software community." For more information: ANGLE plc 01483 295830 Andrew Newland, Group CEO Buchanan Communications 020 7466 5000 Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Further information can be found on www.ANGLEplc.com For more information on Aberro, please visit www.aberrosoftware.com or contactSteve Lafferty at 240.715 3333 x208. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Jan 20227:00 amRNSConcordance of Parsortix with tissue biopsy
13th Jan 20227:00 amRNSUpdate on lab accreditation and ovarian study
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results
27th Sep 20217:00 amRNSParsortix demonstrates ability to isolate CTCs
22nd Sep 20217:00 amRNSStudy shows use of Parsortix to assess PD-L1
20th Sep 20217:00 amRNSParsortix enables gene expression analysis in mPCa
7th Sep 20217:00 amRNSNotice of Interim Results and Webcast
24th Aug 20217:00 amRNSDirector/PDMR Shareholding
9th Aug 20217:00 amRNSStudy highlights superior performance of Parsortix
6th Aug 20211:17 pmRNSIssue of Equity
3rd Aug 20213:13 pmRNSIssue of Equity
28th Jul 20217:00 amRNSContract secured for bespoke assay development
9th Jul 20217:00 amRNSHarvesting CTCs from brain metastasis patients
7th Jul 20216:34 pmRNSDirector/PDMR Shareholding
2nd Jul 202110:45 amRNSIssue of Equity
30th Jun 20213:44 pmRNSResult of AGM
25th Jun 20217:00 amRNSResult of Accelerated Bookbuild
24th Jun 20216:28 pmRNSAccelerated bookbuild to raise up to £20m
18th Jun 202111:42 amRNSAnnual General Meeting update
18th Jun 20217:00 amRNSctDNA and CTCs have differences in EGFR mutations
4th Jun 20217:00 amRNSUpdate on submission for FDA clearance
1st Jun 20217:00 amRNSPotential to prevent breast cancer relapse
20th May 20217:00 amRNSParsortix demonstrates oesophageal cancer utility
19th May 20214:37 pmRNSExercise of options and total voting rights
11th May 20217:00 amRNSParsortix study uncovers targets in TNBC patients
30th Apr 202111:22 amRNSExercise of options and total voting rights
29th Apr 20217:00 amRNSPreliminary Results
26th Apr 20217:00 amRNSOvarian cancer study patient enrolment completed
19th Apr 20212:05 pmRNSSecond Price Monitoring Extn
19th Apr 20212:00 pmRNSPrice Monitoring Extension
19th Apr 202111:05 amRNSSecond Price Monitoring Extn
19th Apr 202111:00 amRNSPrice Monitoring Extension
16th Apr 20217:00 amRNSFirst large-scale pharma services contract secured
15th Apr 20214:10 pmRNSNotice of Preliminary Results and Webcast

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.